Halozyme Therapeutics (HALO) Goodwill & Intangibles (2022 - 2026)

Halozyme Therapeutics (HALO) has 5 years of Goodwill & Intangibles data on file, last reported at $1.5 billion in Q1 2026.

• Goodwill & Intangibles for Q1 2026 came in at $1.5 billion, up 91.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 91.57% YoY), and the FY2025 annual result was $1.6 billion, up 90.78% from the prior year.
• Goodwill & Intangibles declined to $1.5 billion in Q1 2026 per HALO's latest filing, from $1.6 billion in the prior quarter.
• Over five years, Goodwill & Intangibles peaked at $1.6 billion in Q4 2025 and troughed at $765.4 million in Q3 2025.
• A 5-year average of $986.0 million and a median of $898.6 million in 2023 frame the typical range for Goodwill & Intangibles.
• The sharpest annual moves came in 2023 and 2026: Goodwill & Intangibles fell 21.08% in 2023, then jumped 91.57% in 2026.
• A 5-year view of Goodwill & Intangibles shows it stood at $955.7 million in 2022, then slipped by 6.91% to $889.7 million in 2023, then retreated by 7.99% to $818.7 million in 2024, then jumped by 90.78% to $1.6 billion in 2025, then dropped by 1.76% to $1.5 billion in 2026.
• Business Quant data shows HALO's Goodwill & Intangibles at $1.5 billion in Q1 2026, $1.6 billion in Q4 2025, and $765.4 million in Q3 2025.